Kornimate/medical-research-clean huggingface dataset:
study of yoga and mindfulness for psychological and physical wellness

Conditions: Psychological Trauma; PTSD

Summary: the study rationale is to analyze the extent to which adult u.s. or non u.s. veterans or active duty military personnel who participate in the yoga for men (yfm) online yoga and meditation classes report changes in symptoms of psychological trauma, depression, anxiety, stress, sleep quality, and pain. the serial measurement of symptom status over a 12-month period will provide information on the trajectory of change in symptom status, as well as insight into the extent to which this program may be an effective modality for veterans and service members who are experiencing symptoms of psychological trauma, depression, anxiety, stress, sleep quality, and pain. the purpose of this study is to evaluate whether the existing yfm online program is helpful to study qualifying veterans with symptoms of ptsd and related conditions.

yoga is an ancient indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation. it is designed to bring balance and health to the physical, mental, emotional, and spiritual dimensions of the individual. a recent systematic review of 17 studies published between the years 2011-2013 reported that most studies of yoga demonstrated positive changes in psychological or physiological outcomes related to stress. in addition, the practice of yoga also seems to be associated with moderate improvements in cognitive function , which in turn, may be expected to positively impact overall psychological well-being. these selected results provide a strong rationale to examine the effects of yoga for a range of health conditions, in addition to across various setting and by use of different delivery methods. much of the research on mindfulness has been in the area of anxiety and depression. evidence suggests that mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner , can result in reduced symptoms of depression and anxiety .

Eligibility criteria:
inclusion/exclusion form id# __________ visit: screening date: ____________________ inclusion criteria (all must be marked "yes" to be eligible for the study). 1. age 18 years or older and military service member active duty or retired yes ___ no ___ 2. access to a computer and internet service yes ___ no ___ 3. able to read english at 8th grade level or higher. yes ___ no ___ 4. one or more symptoms endorsed on appendix b. yes ___ no ___ exclusion criteria (must be marked "no" to be eligible for the study). 1. never served in the military. yes ___ no ___ is subject eligible for participation? yes_____ no_____
post intensive care optimization through lifestyle intervention

Conditions: ICU Survivor; Muscle Weakness

Summary: the quality of the intensive care unit (icu) has been steadily improving over the years. although improvements in the acute treatment of critically ill patients have been made, a large number of icu survivors suffer from severe physical, cognitive and mental health problems persisting months to years after leaving the icu. physical impairments occur the most and can be very severe, greatly affecting activities in daily life and subsequently the perceived quality of life of icu survivors. although there is an increased awareness of long-term complaints following icu stay, there is currently a knowledge gap on how to enhance the recovery of icu survivors 6 to 12 months post-icu discharge. the overall objective of the current study is to establish the extent of health and functional improvements that can be obtained with an optimized, combined exercise and nutritional intervention in icu survivors 6 to 12 months post-icu discharge.


Eligibility criteria:
inclusion criteria: * aged 18 years and older * minimum icu length of stay of 5 days and/or mechanically ventilated for a minimum of 2 days * persistent physical complaints * community-dwelling, living independently (non-assisted) * mentally competent with a mini-mental state examination (mmse) score of ≥24 * willing to participate in a 20-week multimodal lifestyle intervention exclusion criteria: * any medical condition that may interfere with the safety of the subjects during exercise or any condition that interferes with assessment of the outcome parameters, in the investigators' judgement in consultation with the responsible physician or treating physician/specialist. in case of a contra-indication for mri (e.g., a pacemaker), subjects will be excluded from this measurement but not necessarily from the study. * any medical condition or circumstance where supplementation with the nutritional supplement is potentially contra-indicated. * known allergy to any of the ingredients present in the nutritional supplement. * simultaneous use of other nutritional supplements during the study period (i.e., unwillingness to stop for the duration of the study). * current participation in other scientific research that conflicts with this study (e.g. intervention studies or weight management studies). * no permission to request information from the general practitioner/treating specialist(s) about medical history, medication use. * pregnancy.
gynecologists' feedback on art-birth rates

Conditions: Infertility

Summary: the investigators will examine the hypothesis that women who are given their personalized ivf-prognosis are less likely to overestimate their ivf-live birth rate, as compared to women who do not receive a personalized ivf-prognosis. control group: at the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos. intervention group: at the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized ivf-prognosis (i.e. their chance on a live birth from the current ivf-cycle, including the transfer of fresh and if available cryopreserved embryos, calculated by entering eight background characteristics and five ivf-laboratory results into a prognostic model).

primary outcome: the proportion of women expecting their ivf-live birth rate to be double their calculated ivf-prognosis, directly after their fresh embryo transfer. secondary outcomes: the proportion of men expecting their ivf-live birth rate to be double their calculated ivf-prognosis, directly after their fresh embryo transfer. women's and men's anxiety will be assessed with the reliable 'state-anxiety inventory, (stai-state)' questionnaire, disseminated in coded paper-pencil format on the day of the fresh embryo transfer. patient's infertility-specific distress will be assessed with the reliable 'infertility distress scale (ids)' questionnaire, within two days of the conclusive pregnancy test after the transfer of the last (fresh or cryopreserved) embryo of the studied ivf-cycle.

Eligibility criteria:
inclusion criteria: * couples treated with a 2nd-6th fresh cycle of ivf (every couple can only participate ones in this study). exclusion criteria: * couples treated with: * pre-implantation genetic testing (pgt) * donated oocytes, sperm or embryos * spermatozoa obtained by testicular extraction * hiv-positive diagnosis * embryo transfer on day 2
investigation of pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of somapacitan in subjects with various degrees of impaired renal function compared to subjects with normal renal function

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency; Growth Hormone Deficiency in Children

Summary: the trial is conducted in europe. the aim of the trial is to investigate the steady state exposure of somapacitan in subjects with various degrees of renal impairment (mild, moderate, severe renal impairment, requiring haemodialysis treatment) compared to subjects with normal renal function


Eligibility criteria:
inclusion criteria: * male or female, aged 18-75 years (both inclusive) at the time of signing informed consent * body mass index between 18.5-34.9 kg/sqm (both inclusive) * meeting the pre-defined glomerular filtration rate for any of the renal function groups 1-4 (based on the measured glomerular filtration rate using exogenous sinistrin (inutest®) as a filtration marker) or being in treatment with haemodialysis exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice). male of reproductive age who or whose partner(s) is not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) or male who is not willing to refrain from donating semen for at least 16 days after last trial product administration * any disorder, except for conditions associated with renal impairment in the groups of subjects with reduced renal function, which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol. for example, arterial hypertension, anaemia, impaired glucose tolerance or type 2 diabetes are accepted in the group of subjects with renal impairment
comparing the use of vitamin c (ascorbic acid) in eye burn in subconjunctival injection to topical or oral treatment.

Conditions: Burn

Summary: eye burns may cause a severe permanent damage. one kind of treatment is the use of vitamin c (ascorbic acid). this study will compare between subconjunctival topical and/or systemic route of administration and topical and/or systemic administration.

in order to prevent permanent and severe damage to the eye after eye burn early treatment is mandatory. it is well known and published that the use of vitamin c may contribute to the healing process of such burns, including burns from chemicals or heat. we believe that the route pf administration of the medicine is as important as the kind of medicine and that subconjunctival injection will have better effect and will influence in a favorable manner on the the end result as well as on the time of the healing. in order to be able to compare between cases we made a new definition of the severity of the burn according to the extension of the damage on the cornea, conjunctiva and limbus, and according to the severity and depth of the ischemia. in 3 medical centers 3 protocols of treatment and followup will be compared while only in baruch pade medical center the main route of administration will be subconjunctival on top of the topical treatment.

Eligibility criteria:
inclusion criteria: * eyes clinic patients presented with acute chemical or thermal burn. exclusion criteria:other disease

Keywords: burn eye vitamin c ascorbic acid
transcutaneous auricular vagus nerve stimulation for meniere disease

Conditions: Meniere Disease

Summary: objective: to evaluate the effect of transcutaneous auricular vagus nerve stimulation for the patients meniere disease. methods: we enrolled 88 patients at beijing tongren hospital. all treatments were self-administered by the patients at home after training at the hospital. patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks. tinnitus handicap inventory (thi), dizziness handicap inventory (dhi), pure tone audiometry, visual scale of ear stuffiness and sf-36 were performed to evaluate the therapeutic effects. a difference of p \< 0.05 was considered statistically significant.


Eligibility criteria:
inclusion criteria: 1. age \>=18 and age \<=70. 2. clinical diagnosis of meniere disease. exclusion criteria: 1. history of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2. history of otorhinolaryngology surgery. 3. pregnant or lactating women.

Keywords: meniere disease tavns rct
ultra-wide-field fluorescein angiography in patients with retinal vein occlusion

Conditions: Retinal Vein Occlusion

Summary: the changes of ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography (uwfa)

in this study, the ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion will be evaluated by ultra-wide field fluorescence angiography (uwfa). uwfa has a wider range than conventional angiography, and can clearly observe the peripheral retina. the purpose of this study is to quantitatively analyze these changes and investigate the effect on macular edema and neovascularization secondary to retinal vein occlusion.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18 years or more 2. patients with a diagnosis of crvo,brvo or hrvo without macular edema 3. duration of rvo not more than 4 months 4. naïve patients. patient with previous rvo (more than 12 months before the inclusion date) which completely resolved (normalization of visual acuity and fundus examination) and who experienced a recurrence of rvo are also considered naive 5. patient who agrees to participate to the study and who has given his/her written, informed consent exclusion criteria: 1. patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period 2. active or suspected ocular or periocular infection 3. active severe intraocular inflammation 4. rvo complicated with neovascularization 5. patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-vegf or corticoids intravitreal injections in the study eye 6. patient already included in the study for the treatment of the fellow eye 7. pregnant or breastfeeding woman 8. lack of effective contraception for women of childbearing age 9. patient taking part in an interventional study

Keywords: ischemic index ultra-wide field fundus fluorescein angiography vascular leakage index
mediterranean diet and postprandial lipemia

Conditions: Postprandial Lipemia; Type 2 Diabetes

Summary: the aim of this intervention study was to evaluate in type 2 diabetic patients the effects on postprandial lipemia and other metabolic parameters (in both everyday life conditions and after a standard test meal) of two diets, one moderately rich in cho, rich in fibre and with a low glycemic index (mediterranean diet), and the other low in cho and rich in mufa (low-cho diet).since adipose tissue, mainly through its lipolytic activities, is considered as having a pivotal role in the regulation of postprandial lipid metabolism, a further aim of our study was to clarify the role of adipose tissue in modulating the postprandial lipid response induced by the two dietary approaches by evaluating the activities of lipoprotein lipase (lpl) and hormone-sensitive lipase (hsl).


Eligibility criteria:
inclusion criteria: * type 2 diabetes * stable metabolic control (hba1c\<8.0%) on diet or diet alone or diet+metformin * bmi\<30 kg/m2 and body weight stable during the last six months. * both sexes; only post-menopausal women. * normal fasting lipid levels * no use of hypolipidemic drugs exclusion criteria: * patient with renal (serum creatinine \>1.5 mg/dl) or hepatic (serum transaminases \>three times upper normal values) impairment. * patients with history of cardiovascular disease. * pre-menopausal women. * any other acute or chronic degenerative disease. * anemia (hb\<12 g/dl). * uncontrolled blood pressure. * use of any drugs able to interfere with the study medications

Keywords: mediterranean diet postprandial lipids postprandial glucose high fibre diet low- cho diet high mufa diet dietary approach
informational nudge to improve heart failure prescribing

Conditions: Heart Failure

Summary: this study addresses a critical gap of care for veterans with heart failure (hf). only 1/3 or fewer eligible veterans are receiving recommended sglt2 and mra therapies that save lives and prevents hf hospitalizations. the investigators will compare the effect of clinician directed nudges as strategies to improve the health of veterans with hf.

this study addresses a critical gap in quality of care for veterans with heart failure (hf). only 1/3 or fewer eligible veterans are receiving sglt2 inhibitors and mineralocorticoid receptor antagonists, both medications that save lives and prevents hf hospitalizations. the investigators will combine insights from behavioral science and quality improvement science to create two types of 'nudges' - informational alerts and peer comparison feedback - to increase prescribing of these medications. the investigators will create two types of 'nudges' - informational alerts and peer comparison feedback - to increase prescribing of these medications. the investigators will compare the effect of these two nudge strategies alone and in combination compared to usual care. this project will develop simple, scalable, and low-cost strategies to improve the health of veterans with hf.

Eligibility criteria:
inclusion criteria: * primary care and cardiology clinicians at southern az va health care system working in outpatient clinic setting exclusion criteria: * clinicians who are in training status (resident, fellow) will be excluded.

Keywords: sodium-glucose transporter 2 inhibitors mineralocorticoid receptor antagonists economics, behavioral feedback medical audit
effects of eed on zn absorption and retention in children from a standard dose

Conditions: Environmental Enteric Dysfunction; Zinc Deficiency; Vitamin A Deficiency

Summary: the overall objective is to determine the impact of eed on zinc absorption and homeostasis, and its impact on the absorptive capacity of vitamin a absorption of young children (18-24 months of age) in an austere setting with high rates of diarrhea, stunting, and micro-nutrient deficiencies.

participating children are screened for eed using the lactulose:mannitol ratio test and assigned to one of two groups: +eed or -eed. all participants will be given standard, physiological dose of 3 mg zinc sulfate with a zinc stable isotope tracer on study day 8. on study day 11, 0.5 mg of 13c10-retinyl-acetate will be administered orally to all participants. spot urine samples will be collected twice daily from study days 11-14. complete fecal collections will be obtained for days 11-14. duplicate diets of all foods consumed will be collected on days 11-14. on study day 14, a blood sample will be taken for analysis of vitamin a isotope status.

Eligibility criteria:
inclusion criteria: * absence of apparent health problems that would impair ability to consume regular diet, to tolerate zinc supplements, or to comply with demands of metabolic studies * length for age z-score (laz) between -1.5 to -3.0 * hemoglobin (hgb) ≥ 8 exclusion criteria: * outside age range * hgb \< 8 * chronic illness * recent diarrhea (within past 2 weeks, treated with supplemental zinc) * severe stunting and/or severe acute malnutrition (sam): laz \<-3; weight-for-age z-score (whz) \<-3 or mid-upper arm circumference (muac) \< 115 or edema

Keywords: environmental enteric dysfunction environmental enteropathy zinc vitamin a bangladesh
csapg early warning score

Conditions: Undefined

Summary: the early warning score (ews) has been shown in previous studies to be correlated with mortality and mean hospital stay, but it is unknown whether the implementation of the scale improves mortality and mean hospital stay. this trial aims to study whether the implantation of the ews in a regional hospital reduces the mean hospital stay (primary objective), mortality and complications (secondary objectives). for this, an open clinical trial will be carried out in which the hospitalization floors of the hospital will be administratively divided into two sections (two study branches); the ews scale will be implemented in the computer equipment of one of the sections of each floor, acting the another section as a control branch. all the patients admitted to the participating hospital floors during one year will be included in the study. the mean stay, mortality and complications will be compared between study branches.


Eligibility criteria:
inclusion criteria: * patients admitted during study period to the participant hospital units. exclusion criteria: * none

Keywords: hospital stay mortality clinical deterioration
clinical evaluation of approved and investigational contact lenses

Conditions: Visual Disorder

Summary: this study is a multi-site, 5-visit dispensing, bilateral double-arm parallel group design, double-masked clinical trial using an investigational contact lens and a marketed contact lens. the objective is to evaluate comfort of the contact lenses when worn on a daily wear modality.


Eligibility criteria:
inclusion criteria: * the subject must read, understand, and sign the statement of informed consent and receive a fully executed copy of the form. * the subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. * the subject must be between 18 to 40 years of age at the time of consent. * the subject's vertexed spherical equivalent distance refraction must be in the range of +8.00 to -12.00 in each eye. * subject wears habitual contact lenses a minimum of 4 days per week, eight hours per day. * the subject must have best corrected visual acuity of 20/30 or better in each eye. * the subject must be a habitual frequent replacement daily wear spherical silicone hydrogel soft contact lens wearer in both eyes. * the subject must be able to wear contact lenses for a minimum of 8 hours each day during the study. * the subject must have normal eyes (i.e., no ocular medications or infections of any type). exclusion criteria: * currently pregnant or lactating (subjects who become pregnant during the study will be discontinued). * any ocular or systemic allergies or diseases that may interfere with contact lens wear. * any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. * any known sensitive/allergic to ingredients of opti-free® puremoist® solution. * entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion. * any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (prk), laser-assisted in situ keratomileusis (lasik), etc.). * any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the fda classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear. * any ocular infection. * any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. * participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.